CRISPR Therapeutics Newsroom

CRISPR Therapeutics Analyst Ratings

BenzingaOct 4 23:35

RBC Cuts Price Target on CRISPR Therapeutics to $53 From $60, Keeps Sector Perform Rating

MT NewswiresOct 4 19:29

CRISPR Therapeutics Analyst Ratings

BenzingaAug 12 21:03

Truist Adjusts Price Target on CRISPR Therapeutics to $100 From $120, Maintains Buy Rating

MT NewswiresAug 12 18:12

Crispr Therapeutics AG: Strategic Progress and Strong Financials Bolstering a Buy Rating

TipRanksAug 8 13:22

Crispr Therapeutics AG Poised for Growth: Foroohar Maintains Buy Rating Amid Pipeline Progress and Strong Financials

TipRanksAug 7 13:29

A Quick Look at Today's Ratings for CRISPR Therapeutics(CRSP.US), With a Forecast Between $30 to $105

Futu NewsAug 6 21:00

Crispr Therapeutics AG (CRSP) Receives a Buy From Piper Sandler

TipRanksAug 6 19:29

Crispr Therapeutics Price Target Cut to $94.00/Share From $112.00 by Chardan Capital

Dow JonesAug 6 18:56

Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $94

BenzingaAug 6 18:45

CRISPR Therapeutics Analyst Ratings

BenzingaAug 6 18:14

Barclays Sticks to Its Hold Rating for Crispr Therapeutics AG (CRSP)

TipRanksAug 6 17:51

Chardan Research Adjusts Price Target on CRISPR Therapeutics to $94 From $112, Maintains Buy Rating

MT NewswiresAug 6 17:44

Buy Rating Affirmed for Crispr Therapeutics AG Amid Strong Commercial Prospects and Robust Pipeline Growth

TipRanksAug 6 16:47

Rodman & Renshaw Initiates CRISPR Therapeutics at Buy With $90 Price Target

MT NewswiresAug 2 19:32

TD Cowen Reaffirms Their Sell Rating on Crispr Therapeutics AG (CRSP)

TipRanksJul 23 19:47

TD Cowen Maintains CRISPR Therapeutics(CRSP.US) With Sell Rating, Maintains Target Price $30

Futu NewsJul 23 19:33

Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target

BenzingaJun 27 17:37

CRISPR Therapeutics Analyst Ratings

BenzingaJun 27 17:35

Piper Sandler Reiterates Overweight on CRISPR Therapeutics, Maintains $105 Price Target

BenzingaJun 18 01:14